Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Apr;24(4):666-7.
doi: 10.1038/mt.2016.50.

siRNA Therapeutics for Primary Hyperoxaluria: A Beginning

Dawn S Milliner  1
Affiliations
Comment

siRNA Therapeutics for Primary Hyperoxaluria: A Beginning

Dawn S Milliner. Mol Ther. 2016 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier plots of kidney survival among 168 patients with primary hyperoxaluria (PH) who did not have end-stage renal disease (ESRD) at diagnosis. Patients are shown by quartile of urine oxalate excretion (normal <0.45 mmol/1.73 m2/day). Patients in the highest quartile of urine oxalate excretion of ≥2.4 had the worst renal survival (42% at 20 years following diagnosis), compared with renal survival of 95% 20 years following diagnosis in those who had <1.6 mmol/1.73 m2/day. Reprinted from ref. .
See this image and copyright information in PMC

Comment on

References

    1. Bobbin, ML and Rossi, JJ (2016). RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 56: 103–122. - PubMed
    1. Martin-Higueras, C, Luis-Lima, S and Salido, E (2016). Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. Mol Ther 24: 719–725. - PMC - PubMed
    1. Dutta, C, Avitahl-Curtis, N, Pursell, N, Larsson Cohen, M, Holmes, B, Diwanji, R et al. (2016). Inhibition of glycolate oxidase with Dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type I. Mol Ther 24: 770–778. - PMC - PubMed
    1. Coelho T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819–829. - PubMed
    1. Cochat, P and Rumsby, G (2013). Primary hyperoxaluria. N Engl J Med 369: 649–658. - PubMed

Substances

LinkOut - more resources